+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PCI Biotech  - logo

PCI Biotech is a biopharmaceutical company that produces therapies to fight against cancer through creating photochemical internalisation (PCI) technology platform. This platform is divided into 3 different segments such as: fimaCHEM, fimaVACC and fimaNAc. FimaCHEM is the company's main programme and it focuses on studying bile duct cancer. The fimaVACC studies the cytotoxic effect of therapeutic cancer vaccines. The fimaNAc is used to provide the delivery of nucleic acids: mRNA and siRNA. PCI Biotech was founded in 2000 and is based in Lysaker, Norway. They are a subsidiary of PCI Biotech Holding ASA.

From
From
RNA Vaccine Patent Landscape 2021 - Product Thumbnail Image

RNA Vaccine Patent Landscape 2021

  • Report
  • January 2021
  • 109 Pages
From
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2020 - Product Thumbnail Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
From
From
Melanoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Melanoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 3809 pages
From
From
From
From
From
The Pharmaceutical Market: Norway - Product Thumbnail Image

The Pharmaceutical Market: Norway

  • Report
  • April 2015
  • 67 Pages
From
PCI Biotech Holding ASA - Product Thumbnail Image

PCI Biotech Holding ASA

  • Company Profile
  • May 2021
  • 69 Pages
From
  • 17 Results (Page 1 of 1)
Loading Indicator
adroll